INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 168 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,833,563 | -29.9% | 89,613 | -9.5% | 0.00% | -33.3% |
| Q2 2023 | $4,039,422 | +16.5% | 99,054 | +6.4% | 0.01% | +20.0% |
| Q1 2023 | $3,468,123 | +6.4% | 93,054 | -0.4% | 0.01% | 0.0% |
| Q4 2022 | $3,260,645 | -34.2% | 93,455 | +5.6% | 0.01% | -37.5% |
| Q3 2022 | $4,954,000 | +7.1% | 88,522 | -0.9% | 0.01% | +14.3% |
| Q2 2022 | $4,625,000 | -26.8% | 89,360 | +2.7% | 0.01% | -12.5% |
| Q1 2022 | $6,320,000 | -43.1% | 86,973 | -7.4% | 0.01% | -38.5% |
| Q4 2021 | $11,108,000 | -5.3% | 93,941 | +7.4% | 0.01% | -13.3% |
| Q3 2021 | $11,730,000 | -17.7% | 87,436 | -0.7% | 0.02% | -16.7% |
| Q2 2021 | $14,255,000 | +114.7% | 88,044 | +6.4% | 0.02% | +100.0% |
| Q1 2021 | $6,641,000 | +61.0% | 82,746 | +9.1% | 0.01% | +50.0% |
| Q4 2020 | $4,125,000 | +173.5% | 75,834 | 0.0% | 0.01% | +200.0% |
| Q3 2020 | $1,508,000 | +8.6% | 75,834 | +14.8% | 0.00% | 0.0% |
| Q2 2020 | $1,389,000 | +94.5% | 66,085 | +13.2% | 0.00% | 0.0% |
| Q1 2020 | $714,000 | -19.2% | 58,392 | -3.1% | 0.00% | 0.0% |
| Q4 2019 | $884,000 | +10.0% | 60,244 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $804,000 | -12.4% | 60,244 | +7.5% | 0.00% | 0.0% |
| Q2 2019 | $918,000 | +5.6% | 56,051 | +10.2% | 0.00% | 0.0% |
| Q1 2019 | $869,000 | +22.4% | 50,871 | -2.2% | 0.00% | 0.0% |
| Q4 2018 | $710,000 | -51.2% | 52,038 | +2.4% | 0.00% | -33.3% |
| Q3 2018 | $1,455,000 | +4.6% | 50,829 | -0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,391,000 | +161.0% | 50,847 | +101.2% | 0.00% | +200.0% |
| Q1 2018 | $533,000 | +5.5% | 25,270 | -3.8% | 0.00% | 0.0% |
| Q4 2017 | $505,000 | -12.9% | 26,272 | +12.5% | 0.00% | 0.0% |
| Q3 2017 | $580,000 | +44.3% | 23,343 | -7.2% | 0.00% | 0.0% |
| Q2 2017 | $402,000 | +103.0% | 25,143 | +79.0% | 0.00% | – |
| Q1 2017 | $198,000 | +5.3% | 14,043 | -2.1% | 0.00% | – |
| Q4 2016 | $188,000 | -25.1% | 14,343 | -2.7% | 0.00% | -100.0% |
| Q3 2016 | $251,000 | -19.8% | 14,743 | +0.7% | 0.00% | 0.0% |
| Q2 2016 | $313,000 | – | 14,643 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |